Tumori最新文献

{"title":"A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.","authors":"Antonio Silvani, Enrico Franceschi","doi":"10.1177/03008916231217583","DOIUrl":"10.1177/03008916231217583","url":null,"abstract":"","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"160-161"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139080936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Muscle-invasive bladder cancer in elderly and frail people: Is hypofractionated radiotherapy a feasible approach when no other local options are available?","authors":"Giulia Marvaso, Angelo Vitullo, Giulia Corrao, Maria Giulia Vincini, Mattia Zaffaroni, Riccardo Villa, Federico Mastroleo, Lukasz Kuncman, Dario Zerini, Ilaria Repetti, Chiara Lorubbio, Gennaro Musi, Ottavio De Cobelli, Barbara Alicja Jereczek-Fossa","doi":"10.1177/03008916241252326","DOIUrl":"10.1177/03008916241252326","url":null,"abstract":"<p><strong>Aim: </strong>The study aims to report the feasibility and safety of palliative hypofractionated radiotherapy targeting macroscopic bladder tumors in a monocentric cohort of frail and elderly bladder cancer patients not eligible for curative treatments.</p><p><strong>Methods: </strong>Patients who underwent hypofractionated radiotherapy to the gross disease or to the tumor bed after transurethral resection of bladder tumor from 2017 to 2021 at the European Institute of Oncology IRCCS, were retrospectively considered. Schedules of treatment were 30 and 25 Gy in 5 fractions (both every other day, and consecutive days). Treatment response was evaluated with radiological investigation and/or cystoscopy. Toxicity assessment was carried out according to RTOG/EORTC v2.0 criteria.</p><p><strong>Results: </strong>A total of 16 patients were included in the study, of these 11 received hypofractionated radiotherapy on the macroscopic target volume and five on the tumor bed after transurethral resection of bladder tumor. No grade (G) >2 acute toxicities were described after treatment for both groups. Only one patient in the group receiving radiotherapy on the macroscopic disease reported G4 GU late toxicity. Ten patients had available follow-up status (median FU time 18 months), of them six had complete response, one had stable disease, and three had progression of disease. The overall response rate and disease control rate were 60% and 70%, respectively.</p><p><strong>Conclusion: </strong>Our preliminary data demonstrate that palliative hypofractionated radiotherapy for bladder cancer in a frail and elderly population is technically feasible, with an acceptable toxicity profile. These outcomes emphasize the potential of this approach in a non-radical setting and could help to provide more solid indications in this underrepresented setting of patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"193-202"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11151710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140899705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).","authors":"Desirèe Speranza, Elena Sapuppo, Giuseppe Aprile, Alessandra Auriemma, Francesca Bergamo, Roberto Bianco, Roberto Bordonaro, Giovanni Brandi, Oronzo Brunetti, Carlo Carnaghi, Domenico Ciliberto, Saverio Cinieri, Salvatore Corallo, Ferdinando De Vita, Samantha Di Donato, Francesco Ferraù, Lorenzo Fornaro, Viola Barucca, Elisa Giommoni, Claudio Lotesoriere, Claudio Luchini, Cristina Masini, Monica Niger, Salvatore Pisconti, Ilario Giovanni Rapposelli, Lorenza Rimassa, Chiara Rognone, Maria Grazia Rodriquenz, Lidia Rita Corsini, Daniele Santin, Aldo Scarpa, Mario Scartozzi, Hector Soto Parra, Giuseppe Tonini, Giampaolo Tortora, Paolo Tralongo, Nicola Silvestris","doi":"10.1177/03008916231222761","DOIUrl":"10.1177/03008916231222761","url":null,"abstract":"<p><strong>Introduction: </strong>About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization, and sensitivity to the various possible therapies, including molecular-based treatments. Such rare tumors are described only in case reports or small retrospective series because of their exclusion from clinical trials. This national initiative, here presented, aims to address the following knowledge gap: a) how much does histological diversity translate into clinical manifestation variety? b) are those chemotherapy regimens, recommended for conventional biliary tract cancers, potentially active in rare variants?Therefore, epidemiological, pathological, and clinical characterization of series of rare biliary histotypes/variants, for which therapeutic and follow-up data are available, will be collected.</p><p><strong>Methods: </strong>An Italian task force on rare tumors of the biliary tract (IRaBiCa) has been created, whose initiative is a multicenter retrospective study involving 34 Italian cancer centers.Clinical data from approximately 100 patients will be collected and analyzed. Continuous variables will be presented as median ± standard deviation, while categorical variables will be expressed in terms of frequency. Kaplan-Maier analyses will be used to compare disease free, progression free and overall survival, according to the different histotypes.</p><p><strong>Conclusions: </strong>We expect to gather novel data on rare histotypes of biliary tract cancer that will be useful to support their molecular and immunological characterization.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"203-208"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139703562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved immune checkpoint inhibitors?","authors":"Emanuele Crocetti, Alessandra Ravaioli, Fabio Falcini, Rosa Vattiato, Silvia Mancini, Flavia Baldacchini, Federica Zamagni, Benedetta Vitali, Chiara Balducci, Lauro Bucchi, Orietta Giuliani","doi":"10.1177/03008916241229649","DOIUrl":"10.1177/03008916241229649","url":null,"abstract":"<p><strong>Introduction: </strong>This cross-sectional study was aimed at estimating the number of Italian incident cancer patients in 2020 eligible for, and respondent to, immune checkpoint inhibitors (ICI).</p><p><strong>Methods: </strong>The study is based on publicly available data: the ICI approved until August 2022 by the Italian Medicines Agency (AIFA) with their specific indications and overall observed responses, rther details can be found in the Online Supplementary Materi cancer incidence estimates at 2020 and observed cancer deaths, and published papers with estimates on the frequency of different cancer stage/histology/markers etc. corresponding to AIFA authorizations.</p><p><strong>Results: </strong>In the analyzed period, a total of seven ICI were authorized in Italy for 20 cancer types. The estimated number of ICI-eligible patients in 2020 was 48,400, 14.3% of those tumors (including skin epitheliomas) that may fit AIFA-indications, and 10.5% of all the incident malignant tumors, including skin epitheliomas. The number of patients who may benefit from ICI therapy was 24,052, 49.7% of the ICI-eligible ones, or 5.2% of the overall estimated incident cancers in 2020.</p><p><strong>Conclusions: </strong>In conclusion, although the number of ICI-eligible patients is a relatively small proportion of the yearly burden of cancers, about half of them may respond to ICI-treatment.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"109-115"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11005312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139900492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of low skeletal muscle mass in oropharyngeal cancer patients treated with radical chemo-radiotherapy: A mono-institutional experience.","authors":"Chiara L Deantoni, Aurora Mirabile, Anna Chiara, Laura Giannini, Martina Midulla, Antonella Del Vecchio, Claudio Fiorino, Andrei Fodor, Nadia G Di Muzio, Italo Dell'Oca","doi":"10.1177/03008916231212382","DOIUrl":"10.1177/03008916231212382","url":null,"abstract":"<p><strong>Aims: </strong>Low skeletal muscle mass index (SMI) has recently emerged as an independent prognostic factor in oncological patients and it is linked with poor survival and higher treatment toxicity. The present study aims to determine the possible impact of low SMI on survival and acute toxicity in oropharyngeal patients.</p><p><strong>Methods: </strong>Seventy-six patients with locally advanced oropharyngeal squamous cell carcinoma (stage III-IVC) were treated in our institution with Helical TomoTherapy® (HT - Accuray, Maddison, WI, USA) between 2005 and 2021. All patients received concomitant platinum-based chemotherapy (CT) (at least 200 mg/m2). The SMI was determined using the calculation of cross-sectional area at C3. Twenty patients (26%) presented pre-treatment low SMI, according to Chargi definitions.</p><p><strong>Results: </strong>All patients concluded the treatment. Thirteen patients with low SMI (65%) and 22 patients with normal SMI (39%) presented acute toxicity greater than or equal to grade 3, but this difference was not statistically significant (p-value = 0.25). Overall survival was analyzed in 65 patients, excluding those who finished CT-RT less than six months before the analysis. Overall survival was significantly lower in low SMI versus normal SMI patients (p-value = 0.035). Same difference was observed in N0-N2a patients, suggesting an important role of SMI also in lower nodal burden and putatively better prognosis.</p><p><strong>Conclusions: </strong>Although the results are limited to a small population, our case series has the advantage to be very homogeneous in patients and treatment characteristics. In our setting, SMI demonstrated a crucial impact on overall survival. Further investigation with larger samples is necessary to confirm our results to improve patient outcomes.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"116-123"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11005313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136399350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting.","authors":"Ugo Testa, Germana Castelli, Elvira Pelosi","doi":"10.1177/03008916231202149","DOIUrl":"10.1177/03008916231202149","url":null,"abstract":"<p><p>Anaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma (LUAD). ALK is constitutively activated by gene fusion events between the <i>ALK</i> and other gene fusion partners in about 2-3% of LUADs, characterized by few other gene alterations. <i>ALK</i>-fusions are a druggable target through potent pharmacological inhibitors of tyrosine kinase activity. Thus, several ALK-TKIs (Tyrosine Kinase Inhibitors) of first-, second- and third-generation have been developed that improved the outcomes of <i>ALK</i>-rearranged LUADs when used as first- or second-line agents. However, resistance mechanisms greatly limit the durability of the therapeutic effects elicited by these TKIs. The molecular mechanisms responsible for these resistance mechanisms have been in part elucidated, but overcoming acquired resistance to ALK-derived therapy remains a great challenge. Some new therapeutic strategies under investigation aim to induce long-term remission in <i>ALK</i>-fusion positive LUADs.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"88-95"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11005315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41163936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of primary and recurrent Bartholin's gland carcinoma: A systematic review on behalf of MITO Rare Cancer Group.","authors":"Camilla Turetta, Roberta Mazzeo, Giuseppe Capalbo, Salvatora Miano, Robert Fruscio, Violante Di Donato, Francesca Falcone, Giorgia Mangili, Sandro Pignata, Innocenza Palaia","doi":"10.1177/03008916231208308","DOIUrl":"10.1177/03008916231208308","url":null,"abstract":"<p><p>Bartholin gland carcinoma is an extremely rare disease. Information regarding treatment is scarce and there is no strict consensus on best practice. All studies reporting cases of Bartholin's gland cancer were screened and evaluated for inclusion. Baseline characteristics of studies were extracted. A total number of 290 manuscripts collected were available for the review process. Studies included in a previous systematic review were not duplicated. In total, details of 367 patients were collected, as follows: histological features, clinical presentation, treatment, recurrent rate, treatment of recurrence and outcome. About 35% of Bartholin gland carcinoma were squamous cell carcinoma. Almost 50% of patients presented with advanced stage. The therapeutic approach was mainly surgery, and in 61% of those women lymph node assessment was performed. Recurrence occurred in 21% of cases. Bartholin gland cancer remains a challenge for gynecologic oncologists. Guidelines, centralization to referral centers and standardized therapy are needed.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"96-108"},"PeriodicalIF":2.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89719709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Deantoni et al.","authors":"Erkan Topkan, Efsun Somay, Ugur Selek","doi":"10.1177/03008916241234152","DOIUrl":"10.1177/03008916241234152","url":null,"abstract":"","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"153-154"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is motherhood still possible after pelvic carbon ion radiotherapy? A promising combined fertility-preservation approach.","authors":"Amelia Barcellini, Chiara Cassani, Ester Orlandi, Rossella E Nappi, Federica Broglia, Maria Paola Delmonte, Silvia Molinelli, Alessandro Vai, Viviana Vitolo, Alessandro Gronchi, Gioacchino D'Ambrosio, Lorenzo Cobianchi, Maria Rosaria Fiore","doi":"10.1177/03008916231218794","DOIUrl":"10.1177/03008916231218794","url":null,"abstract":"<p><strong>Introduction: </strong>Preserving the endocrine and reproductive function in young female cancer patients undergoing pelvic radiation is a significant challenge. While the photon beam radiation's adverse effects on the uterus and ovaries are well established, the impact of pelvic carbon ion radiotherapy on women's reproductive function is largely unexplored. Strategies such as oocyte cryopreservation and ovarian transposition are commonly recommended for safeguarding future fertility.</p><p><strong>Methods: </strong>This study presents a pioneering case of successful pregnancy after carbon ion radiotherapy for locally advanced sacral chondrosarcoma.</p><p><strong>Results: </strong>A multidisciplinary approach facilitated the displacement of ovaries and uterus before carbon ion radiotherapy, resulting in the preservation of endocrine and reproductive function.</p><p><strong>Conclusion: </strong>The patient achieved optimal oncological response and delivered a healthy infant following the completion of cancer treatment.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"132-138"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139106742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytisine as a smoking cessation aid: Preliminary observations with a modified therapeutic scheme in real life.","authors":"Paolo Pozzi, Roberto Boffi, Chiara Veronese, Sara Trussardo, Camilla Valsecchi, Federica Sabia, Ugo Pastorino, Giovanni Apolone, Elisa Cardani, Francesco Tarantini, Elena Munarini","doi":"10.1177/03008916231216906","DOIUrl":"10.1177/03008916231216906","url":null,"abstract":"<p><strong>Introduction: </strong>Cigarette smoke accounts for over 90,000 deaths each year in Italy. Tobacco dependence treatment guidelines suggest adopting an integrated pharmacological-behavioral model of intervention. Cytisine is a partial agonist of nicotinic receptors. Trials conducted to date have demonstrated its good efficacy in promoting smoking cessation. The cytisine scheme of treatment consists of 25 days of treatment. A 40-day regimen, with an escalating dose and an extended duration of the treatment, has been in use in many anti-smoking centers in Italy for several years, but to date there are no reports on the use of cytisine with this scheme.</p><p><strong>Methods: </strong>A retrospective, real-life, observational study was conducted between January 2016 and September 2022. The 300 patients who had received at least one dose of study medication were selected. Continuous variables were compared by the Wilcoxon-Mann-Whitney test. Univariate and multivariate logistic regression models were implemented for self-reported seven-day point prevalence for abstinence at three, six and 12 months.</p><p><strong>Results: </strong>The median age of the patients was 59 years, 57% were women. The median smoking exposure was 33.8 pack-years. Self-reported smoking abstinence at three, six and 12 months was 68.7%, 56.3% and 47.3% respectively. 84% completed the cytisine treatment, 31.3% reported adverse events and in 8.3% these led to dropping out of the treatment.</p><p><strong>Conclusion: </strong>Cytisine, administered with a novel therapeutic scheme in the real-life setting of a specialized anti-smoking center, significantly promotes smoking abstinence. However, more studies are needed to assess the tolerability and efficacy of this new regimen.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"124-131"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11005299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139040551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}